Oral Session 2-11C Novel therapies for ALL

[OS2-11C-5] Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with r/r ALL

Hidefumi Hiramatsu¹, Lamis Eldjerou², Kathryn Lund², Kota Tokushige³, Yoko Watanabe³, Stephan A. Grupp^4,5 (1.Dept. of Pediatrics, Kyoto Univ., Kyoto, Japan, 2.Novartis Pharmaceuticals Co., New Jersey, USA, 3.Novartis Pharma KK, Tokyo, Japan, 4.Children's Hospital of Philadelphia, Pennsylvania, USA, 5.Perelman School of Medicine, Univ. of Pennsylvania, Pennsylvania, USA)